NO20052281L - Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden - Google Patents
Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom hudenInfo
- Publication number
- NO20052281L NO20052281L NO20052281A NO20052281A NO20052281L NO 20052281 L NO20052281 L NO 20052281L NO 20052281 A NO20052281 A NO 20052281A NO 20052281 A NO20052281 A NO 20052281A NO 20052281 L NO20052281 L NO 20052281L
- Authority
- NO
- Norway
- Prior art keywords
- drug
- aggregates
- amphiphates
- deformability
- aggregate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Det beskrives kombinasjoner av minst tre amfipatiske substanser som danner aggregatsuspensjoner i en polar væske. Valg av systemkomponenter med minst 2-10 ganger forskjell i løselighet sikrer at aggregatene har ekstenderte, uvanlig adapsjonsdyktige overflater. Dette skyldes en samtidig virkning på aggregatene av minst to mer løselige substanser blant de tre systemkomponenter, hvorav minst én er en aktiv ingrediens og fortrinnsvis et legemiddel, den tredje komponent kan alternativt ha rollen som legemiddel. Det beskrives også anvendelse av kombinasjoner i farmasøytiske preparater som kan transportere legemidlene inn i kroppen hos varmblodige skapninger. Dette er mulig ved at legemiddel kan fylles i aggregatene med høyt fleksibelt og deformerbart belegg, hvilket gjør de resulterende legemiddelbærere sterkt adapsjonsdyktige. Det beskrives også egnede fremgangsmåter og gunstige betingelser for fremstilling av bærer og anvendelse. Det beskrives også nye formuleringer med ikke-steroidale, antiinflammatoriske legemidler (NSAID) basert på komplekse aggregater med minst tre amfipatiske komponenter suspendert i et egnet farmasøytisk akseptabelt, polart væskemedium.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41784702P | 2002-10-11 | 2002-10-11 | |
| US10/357,618 US20040105881A1 (en) | 2002-10-11 | 2003-02-04 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| US10/357,617 US7473432B2 (en) | 2002-10-11 | 2003-02-04 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
| PCT/EP2003/011202 WO2004032900A1 (en) | 2002-10-11 | 2003-10-09 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052281D0 NO20052281D0 (no) | 2005-05-10 |
| NO20052281L true NO20052281L (no) | 2005-07-07 |
Family
ID=32995875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052281A NO20052281L (no) | 2002-10-11 | 2005-05-10 | Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden |
Country Status (21)
| Country | Link |
|---|---|
| EP (5) | EP1815847A3 (no) |
| JP (3) | JP2006505619A (no) |
| KR (1) | KR20050055723A (no) |
| CN (1) | CN1703199B (no) |
| AT (1) | ATE381316T1 (no) |
| AU (1) | AU2003273977B2 (no) |
| BR (1) | BR0315148A (no) |
| CA (1) | CA2498938A1 (no) |
| DE (1) | DE60318227T2 (no) |
| DK (1) | DK1551370T3 (no) |
| EA (1) | EA010407B1 (no) |
| ES (1) | ES2298566T3 (no) |
| HR (1) | HRPK20050421B3 (no) |
| IS (1) | IS7776A (no) |
| MX (1) | MXPA05003744A (no) |
| NO (1) | NO20052281L (no) |
| NZ (1) | NZ538571A (no) |
| PL (1) | PL377202A1 (no) |
| PT (1) | PT1551370E (no) |
| SI (1) | SI1551370T1 (no) |
| WO (1) | WO2004032900A1 (no) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1031346B1 (en) | 1999-01-27 | 2002-05-02 | Idea Ag | Noninvasive vaccination through the skin |
| PT1031347E (pt) | 1999-01-27 | 2002-09-30 | Idea Ag | Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis |
| MXPA02000053A (es) | 1999-07-05 | 2003-07-21 | Idea Ag | Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables. |
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| US20040105881A1 (en) | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| EP1811961A2 (en) * | 2004-11-12 | 2007-08-01 | Idea Ag | Extended surface aggregates in the treatment of skin conditions |
| EP2676680A1 (de) * | 2007-09-13 | 2013-12-25 | Basf Se | Verwendung von Hydrophobin-Polipeptiden als Penetrationsverstärker |
| PL214538B1 (pl) * | 2009-05-28 | 2013-08-30 | P P F Hasco Lek Spolka Akcyjna | Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen |
| CN105434354A (zh) * | 2009-06-03 | 2016-03-30 | 斯昆申技术控股有限责任公司 | 用于治疗深部组织疼痛的制剂 |
| US20120232034A1 (en) | 2009-08-21 | 2012-09-13 | Henk-Andre Kroon | Vesicular formulations |
| GB2503845A (en) * | 2011-03-21 | 2014-01-08 | Gregor Cevc | Optimised preparations of highly adaptable aggregates |
| GB2503844A (en) * | 2011-03-21 | 2014-01-08 | Gregor Cevc | Drug-free compositions and methods for diminishing peripheral inflammation and pain |
| GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
| CA2889664C (en) * | 2012-10-26 | 2020-12-29 | Oxford Nanopore Technologies Limited | Droplet interfaces |
| RU2524649C1 (ru) * | 2013-07-24 | 2014-07-27 | Станислав Анатольевич Кедик | Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма |
| HK1221412A1 (zh) * | 2013-07-31 | 2017-06-02 | Sequessome Technology Holdings Limited | 囊泡 |
| EP3760638A3 (en) * | 2013-09-26 | 2021-05-26 | National University of Singapore | Compositions and methods utilizing lysophosphatidylcholine scaffolds |
| JP6547625B2 (ja) * | 2013-10-25 | 2019-07-24 | 凸版印刷株式会社 | 膜小胞回収デバイス、膜小胞回収方法、及び膜小胞分析方法 |
| ES2879383T3 (es) | 2015-06-30 | 2021-11-22 | Sequessome Tech Holdings Limited | Fórmulas mixtas |
| US12364661B2 (en) | 2015-11-20 | 2025-07-22 | The Regents Of The University Of California | Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
| JP7280624B2 (ja) * | 2017-04-03 | 2023-05-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 経血液脳関門的、経粘膜的及び経皮的薬物送達のための変形可能なナノスケールビヒクル（ｄｎｖ） |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| KR102149190B1 (ko) | 2018-04-09 | 2020-08-28 | 경상대학교산학협력단 | 액중 방전 마이크로젯 약물 전달장치 |
| JP2022529781A (ja) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR102209397B1 (ko) | 2020-07-21 | 2021-01-29 | 경상대학교산학협력단 | 액중 방전 마이크로젯 약물 전달장치 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| DE4107153A1 (de) * | 1991-03-06 | 1992-09-10 | Gregor Cevc | Praeparat zur wirkstoffapplikation in kleinsttroepfchenform |
| CA2067754C (en) * | 1990-08-24 | 2002-06-04 | Gregor Cevc | Preparation for the application of agents in mini-droplets |
| DE4447287C1 (de) * | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
| US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
| CN1320880C (zh) * | 1998-12-23 | 2007-06-13 | 伊迪亚股份公司 | 改进的体内局部无创伤用制剂 |
| PT1031347E (pt) * | 1999-01-27 | 2002-09-30 | Idea Ag | Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis |
-
2003
- 2003-10-09 EP EP06023468A patent/EP1815847A3/en not_active Withdrawn
- 2003-10-09 WO PCT/EP2003/011202 patent/WO2004032900A1/en not_active Ceased
- 2003-10-09 PT PT03757944T patent/PT1551370E/pt unknown
- 2003-10-09 AU AU2003273977A patent/AU2003273977B2/en not_active Ceased
- 2003-10-09 EP EP06023467A patent/EP1829528A3/en not_active Withdrawn
- 2003-10-09 JP JP2005500984A patent/JP2006505619A/ja active Pending
- 2003-10-09 NZ NZ538571A patent/NZ538571A/en not_active IP Right Cessation
- 2003-10-09 HR HR20050421A patent/HRPK20050421B3/xx not_active IP Right Cessation
- 2003-10-09 ES ES03757944T patent/ES2298566T3/es not_active Expired - Lifetime
- 2003-10-09 CN CN2003801013013A patent/CN1703199B/zh not_active Expired - Fee Related
- 2003-10-09 EP EP03757944A patent/EP1551370B1/en not_active Expired - Lifetime
- 2003-10-09 CA CA002498938A patent/CA2498938A1/en not_active Abandoned
- 2003-10-09 DE DE60318227T patent/DE60318227T2/de not_active Expired - Lifetime
- 2003-10-09 AT AT03757944T patent/ATE381316T1/de active
- 2003-10-09 EP EP06023465A patent/EP1815846A3/en not_active Withdrawn
- 2003-10-09 MX MXPA05003744A patent/MXPA05003744A/es active IP Right Grant
- 2003-10-09 BR BR0315148-4A patent/BR0315148A/pt not_active IP Right Cessation
- 2003-10-09 KR KR1020057004979A patent/KR20050055723A/ko not_active Ceased
- 2003-10-09 PL PL377202A patent/PL377202A1/pl not_active Application Discontinuation
- 2003-10-09 EP EP06023466A patent/EP1829527A3/en not_active Withdrawn
- 2003-10-09 EA EA200500632A patent/EA010407B1/ru not_active IP Right Cessation
- 2003-10-09 DK DK03757944T patent/DK1551370T3/da active
- 2003-10-09 SI SI200331142T patent/SI1551370T1/sl unknown
-
2005
- 2005-02-15 JP JP2005037992A patent/JP4555111B2/ja not_active Expired - Fee Related
- 2005-03-30 IS IS7776A patent/IS7776A/is unknown
- 2005-05-10 NO NO20052281A patent/NO20052281L/no not_active Application Discontinuation
-
2008
- 2008-11-04 JP JP2008283199A patent/JP2009108070A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004032900A8 (en) | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | |
| CY1107299T1 (el) | Συμφυρμα με αυξημενh ικανοτητα παραμορφωσης, περιεχοντας τουλαχιστον τρια αμφιπαθη, για βελτιωμενη μεταφορα δια μεσω ημι-διαπερατων μεμβρανων και για τη μη-επεκτατικη εφαρμογη φαρμακων in vivo, ειδικoτερα δια μεσω του δερματος | |
| EA200900270A1 (ru) | Системы регулируемого высвобождения и способ их приготовления | |
| HRP20250148T1 (hr) | Specifični triptamini za uporabu u liječenju poremećaja raspoloženja | |
| AR037629A1 (es) | Formulaciones farmaceuticas que comprenden un derivado de platino | |
| EP1848541A4 (en) | METHOD AND DEVICE FOR THE OPHTHALMIC ADMINISTRATION OF PHARMACEUTICAL ACTIVE SUBSTANCES | |
| DK1589945T3 (da) | Topisk farmaceutisk og/eller kosmetisk dispenseringssystem | |
| AR045039A1 (es) | Dispositivo de administracion de drogas oftalmicas | |
| RU2005138915A (ru) | Сульфонамид замещенные имидазохинолины | |
| CN112359018A (zh) | 用于再生毛细胞和/或支持细胞的方法及组合物 | |
| MA26859A1 (fr) | Forme posologique de medicament commandée par un hydrogel. | |
| AR038385A1 (es) | Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo | |
| AR055363A1 (es) | Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion | |
| CA2430112A1 (en) | Paramyxovirus vector encoding angiogenesis gene and use thereof | |
| WO2020222139A9 (en) | Formulations and methods for drug instillation into the bladder and treatment of bladder ailments | |
| MX2023012741A (es) | Formulaciones farmaceuticas liquidas concentradas de furosemida y metodos para administrar las mismas. | |
| BR9809708A (pt) | Composições farmacêuticas de peptìdeos tendo solubilidade baixa em meio fisiológico | |
| ES2361915T3 (es) | Utilización de la betaína para el tratamiento de la claudicación intermitente. | |
| AR048342A1 (es) | FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423) | |
| EP1152002A4 (en) | PYRROL DERIVATIVES AND CELL DEATH INHIBITORS | |
| EP2231192A4 (en) | DRUG DISPENSING SYSTEM FOR THE ADMINISTRATION OF A WATER-SOLUBLE, CATIONIC AND AMPHIPHILIC PHARMACEUTICAL ACTIVE SUBSTANCE | |
| ECSP109871A (es) | Soluciones farmacéuticas orales que contienen telbivudina | |
| CL2025000209A1 (es) | Formulación farmacéutica estable líquida oral de un agente antiespasmódico | |
| FR2793685B1 (fr) | Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation | |
| NO20062442L (no) | Analgesiske suspensjoner md kontrollert frigivelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |